[A20-65] Ixekizumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V
Last updated 21.01.2021
Project no.:
A20-65
Commission:
Commission awarded on 27.07.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Indication:
Children from the age of 6 years and adolescents (body weight of at least 25 kg) with moderate to severe plaque psoriasis who are candidates for systemic therapy
Result of dossier assessment:
Transfer of added benefit from adults not appropriate; added benefit not proven
Note:
The current version 1.1 of the Benefit assessment replaces version 1.0 published on 2020-11-02.
| Project no. | Title | Status |
|---|---|---|
| A18-14 | Ixekizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-07 | Ixekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-66 | Ixekizumab (spondylitis and spondyloarthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G20-31 | Ixekizumab (plaque psoriasis in children and adolescents) - Addendum to Commission A20-65 | Commission completed |
Federal Joint Committee (G-BA)
2021.01.21 A G-BA decision was published